BioLineRx (BLRX) Other Non-Current Liabilities (2012 - 2025)

BioLineRx's Other Non-Current Liabilities history runs 14 years deep, the most recent figure standing at $3.7 million for Q4 2025.

• In Q4 2025, Other Non-Current Liabilities fell 31.32% year-over-year to $3.7 million; the TTM figure through Dec 2025 stood at $3.7 million (down 31.32% YoY), while the FY2025 annual figure was $3.7 million, down 31.32% from the prior year.
• Other Non-Current Liabilities was $3.7 million for Q4 2025 at BioLineRx, roughly flat from $3.7 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $15.4 million in Q2 2023 to a low of $975000.0 in Q1 2022.
• Historically, Other Non-Current Liabilities has averaged $5.9 million across 5 years, with a median of $4.7 million in 2021.
• Biggest YoY gain for Other Non-Current Liabilities was 2782.97% in 2021; the steepest drop was 81.81% in 2021.
• A 5-year view of Other Non-Current Liabilities shows it stood at $1.9 million in 2021, then surged by 142.55% to $4.5 million in 2022, then surged by 164.63% to $11.9 million in 2023, then sank by 55.02% to $5.4 million in 2024, then plunged by 31.32% to $3.7 million in 2025.
• The last three Other Non-Current Liabilities figures came in at $3.7 million (Q4 2025), $3.7 million (Q3 2025), and $4.4 million (Q2 2025), per Business Quant data.